Suppression by shRNA or KO by the CRISPR-Cas9 gene-editing tool of LIMK1 or LIMK2 reduced the colony formation, decreased proliferation, and induced the morphological changes of different AML cell lines and patient-derived xenograft (PDX) samples, indicating a role for LIMKs in leukaemia tumorigenesis. This evidence concerns the gene LIMK2 and acute myeloid leukemia.